--- title: "ASC30 | PepTracker Pro" url: https://peptrackerpro.com/peptides/asc30 description: "An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # ASC30 Low Evidence An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron. Aliases Ascletis oral GLP-1 Evidence Low Evidence Last Updated 2026-06-08 Reading Time 3 min ## What It Is ASC30 is an investigational oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma (China) using the company's proprietary POTENT (Peptide Oral Transport ENhancement Technology) scaffold. Like orforglipron (Foundayo), ASC30 is a non-peptide GLP-1R agonist that can be taken orally without the food/water timing restrictions required by oral semaglutide. In vitro receptor binding studies show ASC30 is approximately 2–3 times more potent than orforglipron at the GLP-1 receptor, potentially suggesting a higher ceiling for weight loss at equivalent doses. Phase 2 clinical data presented at the American Diabetes Association 2026 Scientific Sessions (June 8, New Orleans) from an n=125 study showed statistically significant and clinically meaningful dose-dependent placebo-adjusted weight reductions at week 13: 5.4% (20 mg), 7.0% (40 mg), and 7.7% (60 mg). No weight loss plateau was observed at 13 weeks across any dose group, suggesting continued efficacy potential with longer treatment. The GI tolerability profile was reported as favorable compared with orforglipron in head-to-head in vitro tolerability assays, attributed to ASC30's biased agonism profile. Ascletis also presented preclinical data for ASC37, an oral GLP-1R/GIPR/GCGR triple agonist peptide using the same POTENT technology platform, and ASC39, a selective amylin type 1 receptor agonist targeting the amylin pathway with high hAMY1R selectivity and minimal calcitonin receptor binding — designed to reduce amylin-mediated nausea. Also known as: Ascletis oral GLP-1 ## Regulatory Status Investigational Phase 2 data presented at ADA 2026 (June 2026). No Phase 3 initiation date confirmed yet. Based in China; U.S. regulatory path not yet announced. Effective: June 2026 View FDA Source (https://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html) ## Why Researchers Study It ASC30 represents a next-generation oral GLP-1 receptor agonist with higher in vitro potency than the first approved oral small-molecule GLP-1 drug (orforglipron/Foundayo). If the 2–3x potency translates clinically to greater weight loss per dose — while maintaining a favorable GI tolerability profile — ASC30 could challenge orforglipron and compete in the oral GLP-1 space without injection requirements. ## Proposed Mechanisms - Selectively activates GLP-1 receptors to suppress appetite via hypothalamic signaling - Non-peptide small-molecule structure enables oral bioavailability without permeation enhancers - Biased agonism profile designed to favor cAMP-mediated signaling (weight loss) over beta-arrestin (GI side effects) - POTENT technology platform optimizes oral transport across gastrointestinal epithelium - No food or water timing restrictions due to non-peptide scaffold ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 2) | Adults with obesity (n=125); once-daily oral doses of 20, 40, 60 mg vs placebo, 13 weeks | Placebo-adjusted weight loss of 5.4% (20 mg), 7.0% (40 mg), and 7.7% (60 mg) at week 13; no plateau observed | Source: https://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html | | In vitro | GLP-1 receptor binding and cAMP assay vs orforglipron | ASC30 approximately 2–3x more potent than orforglipron at the GLP-1 receptor in vitro | Source: https://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Researching ASC30? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=asc30) ## Safety & Cautions - Only 13-week Phase 2 data available as of June 2026 — long-term efficacy and safety unknown - Weight loss at 13 weeks (7.7% max) is consistent with early orforglipron data but longer trials are needed to establish competitive efficacy - In vitro potency advantage has not yet been confirmed in head-to-head clinical trials - China-based development; U.S. clinical trial and regulatory pathway not yet announced - Not FDA-approved and not in Phase 3 ## Comparisons See how ASC30 compares to related peptides: ASC30 vs Aleniglipron: https://peptrackerpro.com/compare/asc30-vs-aleniglipron ASC30 vs ASC39: https://peptrackerpro.com/compare/asc30-vs-asc39 ASC30 vs Danuglipron: https://peptrackerpro.com/compare/asc30-vs-danuglipron ASC30 vs Orforglipron: https://peptrackerpro.com/compare/asc30-vs-orforglipron ASC30 vs Semaglutide: https://peptrackerpro.com/compare/asc30-vs-semaglutide ASC30 vs Tirzepatide: https://peptrackerpro.com/compare/asc30-vs-tirzepatide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Ascletis Pharma — ADA 2026: ASC30 Phase 2 Clinical Data and ASC37/ASC39 Preclinical Findings PubMed (https://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html) 2. [2] BioSpace — Ascletis Reinforces Obesity Portfolio at ADA 2026, Showcasing ASC30 and Pipeline PubMed (https://www.biospace.com/press-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39) ### Keep researching in the app - Log ASC30 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=asc30 Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. View Details: https://peptrackerpro.com/peptides/aleniglipron \+ Compare: https://peptrackerpro.com/compare?select=aleniglipron Track in App: https://app.peptrackerpro.com/?add=aleniglipron ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/danuglipron \+ Compare: https://peptrackerpro.com/compare?select=danuglipron Track in App: https://app.peptrackerpro.com/?add=danuglipron ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/orforglipron \+ Compare: https://peptrackerpro.com/compare?select=orforglipron Track in App: https://app.peptrackerpro.com/?add=orforglipron ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "ASC30", "description": "An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron.", "url": "https://peptrackerpro.com/peptides/asc30", "lastReviewed": "2026-06-08", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "ASC30", "item": "https://peptrackerpro.com/peptides/asc30" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Researchers tracking next-generation oral GLP-1 receptor agonists?", "acceptedAnswer": { "@type": "Answer", "text": "ASC30 is a research peptide studied in preclinical models. An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron." } }, { "@type": "Question", "name": "Those following the competitive oral obesity drug landscape post-Foundayo approval?", "acceptedAnswer": { "@type": "Answer", "text": "ASC30 is a research peptide studied in preclinical models. An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron." } }, { "@type": "Question", "name": "Investors and analysts monitoring the global obesity drug pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "ASC30 is a research peptide studied in preclinical models. An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron." } }, { "@type": "Question", "name": "Healthcare providers interested in emerging oral alternatives to injectables?", "acceptedAnswer": { "@type": "Answer", "text": "ASC30 is a research peptide studied in preclinical models. An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron." } } ] } ] ```